[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359853-105":59,"doc-detail-359853-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","plasmachord-a-machine-learning-approach-to-distinguish-clonal-hematopoiesisderived-variants-in-liquid-biopsies-from-patients-with-solid-tumors","plasmaCHORD - A Machine Learning Approach to Distinguish Clonal Hematopoiesis–Derived Variants in Liquid Biopsies from Patients with Solid Tumors","","Targeted next-generation sequencing of cell-free DNA enables comprehensive molecular profiling to guide genotype-targeted therapy selection, yet clonal hematopoiesis (CH) variants create a major confounding signal in liquid biopsies. The study develops plasma Clonal Hematopoiesis Origin Detection (plasmaCHORD), a machine learning model using fragment, variant, and patient features to differentiate tumor versus CH origin. Performance is evaluated against matched reference tumor and white blood cell sequencing and applied to independent and trial-based validation, improving accuracy for clinically significant genes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/plasmachord-a-machine-learning-approach-to-distinguish-clonal-hematopoiesisderived-variants-in-liquid-biopsies-from-patients-with-solid-tumors/359853/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/plasmachord-a-machine-learning-approach-to-distinguish-clonal-hematopoiesisderived-variants-in-liquid-biopsies-from-patients-with-solid-tumors/359853.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does plasmaCHORD address in liquid biopsies?","Question",{"text":113,"@type":114},"It distinguishes variants derived from clonal hematopoiesis from true tumor-derived variants in cfDNA assays, reducing misinterpretation for genotype-targeted therapies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is the plasmaCHORD model trained and validated?",{"text":118,"@type":114},"It is trained using a training cohort of variants from solid tumor patients, assessed against reference origin determined from matched white blood cell and tumor sequencing, then applied to an independent validation cohort and clinical trial samples.",{"name":120,"@type":111,"acceptedAnswer":121},"What features does plasmaCHORD use to determine variant origin?",{"text":122,"@type":114},"The model includes fragment-, variant-, and patient-level features extracted from plasma cfDNA sequencing to classify each detected variant as tumor or CH derived.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},359853,1790171436,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","plasmaCHORD: A Machine Learning Approach to Distinguish Clonal Hematopoiesis–Derived Variants in Liquid Biopsies from Patients with Solid Tumors  \nJenna V. Canzoniero1,2, Daniel Rabizadeh1, Ilias Ziakas1,2, Jaime Wehr1,2, Archana Balan1,  \nAmna Jamali1,2, Blair V. Landon1, Lavanya Sivapalan1, Susan Scott1, Gavin Pereira1, Vincent K. Lam1, Christine L. Hann1, Christine M. Lovly3, Jessica Tao1,2, Patrick M. Forde1, Joseph C. Murray1,4, Mark Sausen5, Gerrit A. Meijer6, Geraldine R. Vink7, Remond J.A. Fijneman6; The MEDOCC Group, Victor E. Velculescu1, Jillian Phallen1, Robert B. Scharpf1,8, and Valsamo Anagnostou1,2,4,9  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Targeted next-generation sequencing (NGS) of cellfree DNA (cfDNA) enables comprehensive molecular profiling and can guide the selection of genotype-targeted therapies. However, the detection of variants derived from clonal hematopoiesis (CH) is a significant confounder in liquid biopsies.\u003Cbr>Experimental Design: Using a training cohort of 426 variants identified in cfDNA NGS from 225 patients with stage I to IV solid tumors, we developed plasma Clonal Hematopoiesis ORigin Detection (plasmaCHORD), a machine learning model that includes fragment-, variant-, and patient-level features to distinguish between tumor and CH origin for each variant detected by liquid biopsies. Model performance was assessed by comparison with the reference origin for each plasma variant determined from matched white blood cell and tumor NGS. Following the locking of the model parameters, we applied plasmaCHORD to an independent validation cohort of 1,418 plasma variants\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | detected in 114 patients with metastatic cancers, as well as to cfDNA NGS from patients enrolled in a prospective clinical trial (NCT05585684) .\u003Cbr>Results: plasmaCHORD predicted tumor origin versus CH origin in the training set with high accuracy (AUC ¼ 0.94). In the independent validation cohort, the locked model maintained similar overall accuracy (AUC ¼ 0.9) and demonstrated significant improvement in accuracy for clinically significant genes. When applied to clinically challenging cases in the context of a precision oncology clinical trial, plasmaCHORD precisely determined variant origin, preventing mismatches with genotype-targeted therapies.\u003Cbr>Conclusions: plasmaCHORD, a multifeature machine learning model, can significantly enhance the ability to identify bona fide tumor variants in routine plasma-only NGS, addressing a critical need for implementing liquid biopsy–guided therapy by minimizing misinterpretation caused by CH. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nAnalysis of cell-free DNA (cfDNA) in liquid biopsies has emerged asan efficient, minimally invasive method for comprehensive genomic  \n1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medici","cbCaicZQ9XalZCwe","https://ap.wps.com/l/cbCaicZQ9XalZCwe","pdf",5133991,16,"English","# Introduction\n## Problem context: cfDNA and clonal hematopoiesis confounding\n# Purpose\n# Experimental Design\n# Results\n# Conclusions","[{\"question\":\"What problem does plasmaCHORD address in liquid biopsies?\",\"answer\":\"It distinguishes variants derived from clonal hematopoiesis from true tumor-derived variants in cfDNA assays, reducing misinterpretation for genotype-targeted therapies.\"},{\"question\":\"How is the plasmaCHORD model trained and validated?\",\"answer\":\"It is trained using a training cohort of variants from solid tumor patients, assessed against reference origin determined from matched white blood cell and tumor sequencing, then applied to an independent validation cohort and clinical trial samples.\"},{\"question\":\"What features does plasmaCHORD use to determine variant origin?\",\"answer\":\"The model includes fragment-, variant-, and patient-level features extracted from plasma cfDNA sequencing to classify each detected variant as tumor or CH derived.\"}]","plasmaCHORD - A Machine Learning Approach to Distinguish Clonal Hematopoiesis–Derived Variants in Liquid Biopsies from Patients with Solid Tumors | PDF",1790138018,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e6ed36a3eccc01ad1faa5110b26c9ec.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7db7792edffdfef6987bf40f1bde5396.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43f30620dd0544248c54c119ac619f65.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b998c9f4420e89c302705fa919d5f0e.webp",980,1311]